Rezpegaldesleukin: A New Era in Atopic Dermatitis Treatment?
San Francisco, February 10, 2026 – Nektar Therapeutics announced promising results from the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, offering hope for individuals battling moderate-to-severe atopic dermatitis (AD). The data, released today, demonstrate sustained disease control and even deepening of responses over time, potentially reshaping the treatment landscape for this chronic inflammatory skin condition.
Understanding the Breakthrough: Targeting Regulatory T Cells
Rezpegaldesleukin represents a first-in-class approach to AD treatment. Unlike existing therapies that broadly suppress the immune system, this biologic focuses on bolstering the body’s natural regulatory T cells (Tregs). Tregs play a crucial role in maintaining immune balance and preventing autoimmune reactions. By stimulating Treg proliferation, rezpegaldesleukin aims to restore immune homeostasis and alleviate AD symptoms.
Sustained Relief: Long-Term Efficacy Data
The REZOLVE-AD Phase 2b study, involving 393 patients, revealed significant benefits with both monthly (Q4W) and quarterly (Q12W) maintenance dosing regimens. A substantial proportion of patients maintained EASI-75 responses (a 75% improvement in eczema severity) – 71% with monthly dosing and 83% with quarterly dosing. Similarly, vIGA-AD 0/1 responses (indicating clear or almost clear skin) were maintained by 85% and 63% of patients, respectively. Notably, the study showed a two- to five-fold increase in EASI-100 response rates – meaning complete skin clearance – in the 24 µg/kg dosing groups.
These findings suggest that rezpegaldesleukin doesn’t just provide initial symptom relief, but can lead to continued improvement and durable control of the disease. “These data show that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis,” stated Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences.
Safety and Tolerability Profile
The safety profile of rezpegaldesleukin remained consistent with previously reported results, with no new safety concerns identified during the 36-week maintenance period. Discontinuation rates due to adverse events were low at 3.5%, and the most common side effect, injection site reactions, were generally mild.
Looking Ahead: Phase 3 Trials and Beyond
The positive maintenance data support the advancement of rezpegaldesleukin into pivotal Phase 3 clinical trials, evaluating both monthly and quarterly maintenance dosing. Nektar Therapeutics anticipates a potential Biologics License Application (BLA) submission in 2029. The company also highlighted the potential for rezpegaldesleukin to offer advantages over current treatments, including less frequent dosing and a novel mechanism of action that doesn’t appear to carry the same risks as other therapies.
“Importantly, we don’t see any increased risk of incidence of conjunctivitis, oral herpes, oral ulcers or malignancies with this MOA as has been observed with other mechanisms,” noted Dr. David Rosmarin, Chair of Dermatology at Indiana University School of Medicine.
The Potential Impact on Atopic Dermatitis Management
Atopic dermatitis affects approximately 30 million people in the United States, and current treatments don’t perform for everyone. Rezpegaldesleukin’s unique approach, targeting the root cause of immune dysregulation, could offer a much-needed alternative for patients who haven’t found relief with existing therapies. The potential for less frequent dosing – quarterly injections – could also significantly improve patient convenience, and adherence.
FAQ
Q: What is rezpegaldesleukin?
A: Rezpegaldesleukin is a novel biologic that stimulates regulatory T cells to restore immune balance in atopic dermatitis.
Q: How often would patients need to receive treatment?
A: Clinical trials are evaluating both monthly and quarterly dosing schedules.
Q: Is rezpegaldesleukin safe?
A: The safety profile observed in clinical trials has been favorable, with no new safety concerns identified.
Q: When might rezpegaldesleukin be available to patients?
A: Nektar Therapeutics anticipates a potential BLA submission in 2029.
Did you know? Rezpegaldesleukin has also received Fast Track designation from the FDA for severe alopecia areata.
Pro Tip: Discuss potential treatment options, including emerging therapies like rezpegaldesleukin, with your dermatologist to determine the best course of action for your individual needs.
Stay informed about the latest advancements in atopic dermatitis treatment. Visit Nektar Therapeutics’ Investor Relations page for updates on the REZOLVE-AD study and future developments.
Keep reading